Oncotelic Therapeutics, Inc. (OTLC)
OTCMKTS · Delayed Price · Currency is USD
0.03834
-0.00306 (-7.39%)
At close: Aug 18, 2026
Oncotelic Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 0.25 | - | - | 0.07 | - | - | |
Revenue Growth | - | - | - | -95.98% | - | - |
Gross Profit | 0.25 | - | - | 0.07 | - | - |
Selling, General & Admin | 5.76 | 2.98 | 0.38 | 0.57 | 4.85 | 5.47 |
Research & Development | 0 | 0 | - | 0.06 | 0.76 | 3.66 |
Operating Expenses | 5.77 | 2.99 | 0.38 | 0.63 | 5.61 | 9.13 |
Operating Income | -5.52 | -2.99 | -0.38 | -0.56 | -5.61 | -9.13 |
Interest Expense | -1.09 | -0.89 | -0.86 | -1.04 | -2.97 | -2 |
Other Non Operating Income (Expenses) | 1.05 | 0.36 | -0.26 | -0.15 | 0.68 | 0.29 |
EBT Excluding Unusual Items | -5.56 | -3.51 | -1.49 | -1.76 | -7.91 | -10.84 |
Impairment of Goodwill | - | - | -3.2 | -6.08 | -4.11 | - |
Gain (Loss) on Sale of Investments | 365.65 | 365.35 | - | 0.01 | - | - |
Gain (Loss) on Sale of Assets | - | - | - | - | 16.95 | - |
Legal Settlements | -0.2 | -0.2 | - | - | - | - |
Other Unusual Items | -1.06 | -1.06 | -0.09 | -0.37 | -0.26 | 0.32 |
Pretax Income | 358.83 | 360.57 | -4.78 | -8.21 | 4.68 | -10.52 |
Income Tax Expense | 111.55 | 111.55 | - | - | - | - |
Earnings From Continuing Operations | 247.28 | 249.02 | -4.78 | -8.21 | 4.68 | -10.52 |
Minority Interest in Earnings | 0.21 | 0.25 | 0.26 | 0.3 | 0.42 | 1.13 |
Net Income | 247.5 | 249.28 | -4.52 | -7.9 | 5.09 | -9.39 |
Net Income to Common | 247.5 | 249.28 | -4.52 | -7.9 | 5.09 | -9.39 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 440 | 421 | 404 | 384 | 384 | 303 |
Shares Outstanding (Diluted) | 440 | 421 | 404 | 384 | 457 | 303 |
Shares Change | 7.93% | 4.12% | 5.29% | -16.01% | 50.89% | 244.02% |
EPS (Basic) | 0.56 | 0.59 | -0.01 | -0.02 | 0.01 | -0.03 |
EPS (Diluted) | 0.56 | 0.59 | -0.01 | -0.02 | 0.01 | -0.03 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 100.00% | - | - | 100.00% | - | - |
Operating Margin | -2206.59% | - | - | -806.96% | - | - |
Profit Margin | 98998.02% | - | - | -11290.13% | - | - |
EBITDA | - | - | - | -0.55 | -5.6 | -9.06 |
D&A For EBITDA | - | - | - | 0.01 | 0.01 | 0.06 |
EBIT | -5.52 | -2.99 | -0.38 | -0.56 | -5.61 | -9.13 |
Effective Tax Rate | 31.09% | 30.94% | - | - | - | - |
Revenue as Reported | - | - | - | 0.07 | - | - |